Front-line management of diffuse large B cell lymphoma

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 642-645

  Cabanillas, Fernando ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

large cell lymphoma; management; review

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ADVANCED CANCER; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CONSENSUS; DRUG EFFICACY; DRUG USE; FOLLICULAR LYMPHOMA; HOSPITAL SERVICE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; PREDNISONE; VINCRISTINE;

EID: 77958498166     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833ed848     Document Type: Review

References (21)

1. Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with Adriamycin. Cancer Res 1973; 33:3024-3028.
2. McKelveyEM, GottliebJA, WilsonHE. Hydroxyldaunomycin(Adriamycin)combi- nation chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
3. Fisher RI, DeVita VTJ, Hubbard SM, et al. Diffuse aggressive lymphoma: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Int Med 1983; 98:304-309.
4. Skarin AT, Cannellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1:91-98.
5. Connors JM, Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions:1987 update and additional observations. Semin Hematol 1988; 25:41-46.
6. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
7. Maloney D, Grillo-Lopez A, White C, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodg-kin's lymphoma. Blood 1997; 90:2188-2196.
8. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
9. Coiffier B, Ketterer N, Engert A, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsed or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
10. Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP alone for localized intermediate and high grade non-Hodgkin's lymphoma: a Southwest Oncology Group study. J Clin Oncol 1996; 15:411. (abstract 1257).
11. Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004; 22:2982-2984.
12. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
13. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104:634-641.
14. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104:626-633.
15. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
16. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-116.
17. Salles G, Seymour J, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after responseto immunochemotherapy. J Clin Oncol 2010; 28:15s; abstract 8004.
18. Habermann T, Weller E, Morrison V, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab(MR) or observation in patients 60 years of age and older with diffuse large B-Cell lymphoma (DLBCL). Blood 2003; 102:abstract 8.
19. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of borte-zomib plus chemotherapy within molecular subtypes of diffuse large B-celllymphoma. Blood 2009; 113:6069-6076.
20. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4952-4957.
21. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91:496-502.